Background: Cell therapy is a potential therapeutic approach for neurodegenerative disorders. Human umbilical cord bloodderived mesenchymal stem cells (hUCB-MSCs) are an appropriate source of stem cells for use in various cell-based therapies. Objectives: In this study, we examined a real-time PCR approach for neural differentiation of hUCB-MSCs in vitro. Materials and Methods: MSCs were cultured in DMEM medium supplemented with 10% FBS in a humidified incubator equilibration at 5% CO2 and 37°C. For the neural differentiation of MSCs, the DMEM was removed and replaced with pre-induction media (retinoic acid [RA], basic fibroblast growth factor [bFGF], and epidermal growth factor [EGF]) and basal medium for two days. They were then cultured in nerve growth factor (NGF), 3-isobutyl-1-methylxanthine (IBMX), ascorbic acid (AA), and basal medium for six days. We also monitored the expression of markers for neural differentiation with real-time PCR. Results: The results of real-time PCR showed that the
Front Pharmacol. 2017 Sep 8 Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Galieva LR1, Mukhamedshina YO1,2, Arkhipova SS1, Rizvanov AA1. Author information Abstract At present there is no effective treatment of pathologies associated with the death of neurons and glial cells which take place as a result of physical trauma or ischemic lesions of the nervous system. Thus, researchers have high hopes for a treatment based on the use of stem cells (SC),
Diabetes mellitus (DM) instigates a cascade of events leading to vascular damage and poor recovery after ischemic stroke. Our previous studies have found that treatment of stroke with bone-marrow-stromal cells initiated at 24h after stroke improves functional recovery in non-DM rats, but not in DM rats. Effective therapy for stroke in the non-DM population may not necessarily transfer to the DM population, prompting the need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke in the DM population. In this study, we hypothesize that treatment of stroke with human umbilical cord blood cells (HUCBCs) promotes neurorestorative effect in DM rats.. Methods: Type one DM (T1DM) was induced with a single injection of streptozotocin (60 mg/kg, ip) to adult male Wistar rats. These rats were subjected to 2h MCAo and were randomized to intravenous injection via tail-vein with: 1) phosphate-buffered saline control; 2) HUCBCs (5x106) at 24 hours after MCAo. A ...
In this study, after 21 days of ceasing CCl 4 , both placebo-treated and untreated cirrhotic mice showed reduced liver damage as indicated by a decrease of AST/ALT index, recovery of histology, and reduction of fibrosis-related gene expression. Presumably, the liver of these mice were capable of self-regeneration. The cause of the self-regeneration has been explained by the ceasing of CCl 4 administration during the 21 days of treatment. Other studies have shown similar results to our study Carvalho et al., 2008 Kuo et al., 2008 .. However, our study uniquely demonstrates that stem cell treatment in cirrhotic mice was better for restoring liver function and histology (significantly better than placebo treatment). The effects of stem cell treatment in our mouse model of liver cirrhosis may be attributed to stem cell immunomodulation, stem cell homing and differentiation, and secreted cytokines Berardis et al., 2015 .. In terms of stem cell therapy for liver cirrhosis, there are several routes for ...
Stem Cells International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of stem cell biology and applications. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.
Robust and large-scale expansion of umbilical cord blood stem cells in vitro is necessary for widening the usage of transplantation therapies for the treatment of hematological and immune diseases. The lack of understanding of the complex inter-cellular networks regulating stem cell fate in culture explains the low success met so far for the ex vivo expansion of hematopoietic stem cells. The development of a mathematical model of in vitro hematopoiesis coupled with gene expression profiling led to predictions about the secreted factors that play a crucial role in regulating hematopoietic stem cell self-renewal in culture. We tested 18 putative molecules predicted to display effects on primitive progenitor (Long-Term Culture-Initiating Cell; LTC-IC) output, functionally validating three stimulators (VEGF, PDGF, EGF) and three inhibitors (TGFβ, CCL4, CXCL10). Combinatorial studies with the stimulatory molecules showed less-than additive effects, perhaps related to redundant signaling mechanisms. Small
Umbilical cord blood (UCB) is an alternative hematopoietic stem cell (HSC) source that can ameliorate several diseases through transplantation. The purpose of this project is to analyze clinical studies comparing HSCs from a single cord blood unit (CBU) to HSCs from bone marrow, and to explore methods of increasing limited amounts of HSCs. It was found that UCB transplantation in adults is a viable method when a matched bone marrow transplant cannot be identified. Further clinical studies using two CBUs suggest better engraftment and lower risk of relapse. However, double cord blood transplantation has been faced with the challenge of single unit dominance in most studies. Ex vivo expansion of UCB HSCs is another promising method to overcome limited HSC counts.
CD34+ cells were isolated from a total of 27 cord blood samples, and the number of MNCs as well as CD34+ cells was analyzed in a Neubauer chamber. As shown in Table 1, the concentration of CD34+ cells was 28 cells/mm3 of cord blood (yield after Ficoll and MACS procedure). The purity of this cell fraction was 93.2 ± 3.6% (87-99%; N = 10). Since 22.2 ± 11.3% (12.5-50.6%) of the CD34+ cells were dead, the average frequency of viable CD34+ among total cells was 71.0 ± 13.1% (39.4-86.5%).. CD34+ cells were cultured with three combinations of growth factors (Figure 1). With TPO + FL + KL, the average increase in cell number in 9 samples studied was 3.55 ± 1.6-fold after 7 days of culture. Only 1 sample (3.a) showed a 0.56-fold decrease in cell number on day 4, but by day 7 the number of the cells in this sample had increased. The observation of individual cultures (Figure 1) showed some heterogeneity among samples, particularly when TPO + FL was used. With this combination of growth factors, the ...
Find all Foetal Cord Blood Karyotype Bone Marrow Labs in Bisru,Gurgaon. Now View Prices, Normal Range, Sample Results & Book Online for Foetal Cord Blood Karyotype Bone Marrow Labs in Bisru Gurgaon only on | Practo
Find all Foetal Cord Blood Karyotype Bone Marrow Labs in Ravi Nagar,Gurgaon. Now View Prices, Normal Range, Sample Results & Book Online for Foetal Cord Blood Karyotype Bone Marrow Labs in Ravi Nagar Gurgaon only on | Practo
Although recent studies have demonstrated the in vitro hepatic differentiation potential of mesenchymal stem cells (MSCs), the evidence supporting the in vivo engraftment of MSCs, hepatic differentiation and improvement of hepatic function is still lacking. We investigated in vivo hepatic differentiation potential and therapeutic effect of cord blood derived-MSCs (CBMSCs) transplantation in a cirrhotic rat model. CBMSCs (2x106) were infused in Wistar rats with thioacetamide-induced chronic liver injury. Biochemical markers, liver fibrosis and engraftment of CBMSCs were assessed. Infused CBMSCs were detected in the perivascular or fibrous region of the liver and did not acquire mature hepatic phenotypes. There was no difference in biochemical markers and in the area of liver fibrosis between the experimental and placebo groups. After infusion of CBMSCs in our experimental cirrhotic rat model we did not observe an improvement of liver function and liver fibrosis. Inversely, CBMSCs could have a ...
The two most widely used sources of hematopoietic stem cells for allogeneic transplants in pediatric practice are bone marrow BM and cord blood CB. While bone marrow transplantation BMT is reaching its 30th year of application, human umbilical cord blood transplantation HUCBT is approaching its 10th. Although these procedures have basically the...
Oxidative stress is associated with the development of various diseases including cancer, arteriosclerosis, diabetes mellitus, hypertension and metabolic syndrome. However, little is known about the involvement of 8-hydroxydeoxyguanosine (8-OHdG) dur
Bulgular: Otuz taze KK nitesinde her KK i in ortalama de erler: Toplam ekirdekli h cre say s (TNC): 93,8 30,1x107, CD34+: 3,85 2,55x106, ALDH+: 3,14 2,55 x106, CFU-GM: 2,64 1,96x105. On dokuz KK nitesinde donma zme sonras h cre de erleri: TNC: 32,79 17,27x107, CD34+: 2,18 3,17x106, ALDH+: 2,01 2,81x106, CFUGM: 0,74 0,92x105 dir. Bulgular m z; taze KK da TNC, CD34 ve ALDH; CFU-GM, CFU-GEMM ve BFU-E ile korelasyon g sterirken (TNC, r=0,47, r=0,35, r=0,41; CD34+, r=0,44, r=0,54 r=0,41; ve ALDH, r=0,63 r=0,45 r=0,6) donma zme sonras KK da korelasyon s ras yla CFU-GM, CFU-GEMM, ve BFU-E i in, TNC r=0,59, r=0,46, r=0,56, CD34+ r=0,67, r=0,48, r=0,61 ve ALDH r=0,61, r=0,67, r=0,67 olarak saptanm t r. B t n bulgular m z istatistiksel olarak anlaml km t r ...
Objective: Cyclosporin A (CsA), effective in prophylaxis and treatment of graft-vs-host disease (GVHD) after human allogeneic transplantation, blunts T-cell responses by inhibiting nuclear factor of activated T cells 1 (NFAT1) activation. This laboratory has shown that NFAT1 protein expression is severely reduced in human UCB (umbilical cord blood) T cells. Since UCB is increasingly used as a hematopoietic stem cell source in allogeneic transplantation, it is important to determine whether CsA sensitivity in UCB differs from that of adult T cells.,br /,,br /,Methods: Surface flow cytometric analysis, intracellular cytokine staining, flow cytometric analysis of cell death, and thymidine incorporation were used in this study to determine T-cell activation and effector functions during primary and secondary stimulation in the presence of CsA.,br /,,br /,Results: Although we observed differential CsA sensitivity of T-cell activation marker (CD69, CD45RO, CD25) upregulation comparing UCB and adult, ...
With the goal of deriving clinically safe USSCs, we aimed to culture established USSCs in the serum- and animal component-free medium, USSC growth mediumACF. We observe that USSCs continue to proliferate in USSC growth mediumACF, but after one to three passages, the cells aggregate and grow in suspension as spheres. We show that spheres can be dissociated and can continue to grow for five passages, as long as they are dissociated before the sphere becomes cystic. We also show the spheres can revert to monolayer growth when provided with extracellular matrix support or when plated in medium containing fetal calf serum. Cells passaged in USCC growth mediumACF maintained their gene expression profile as judged by Sox2, Brachyury, Pax6 and Gata6 expression. Cells also maintained their capacity to form bone-like Alizarin red positive cells, SPC positive epithelial cells and β-tubulin III positive neuronal cells after directed differentiation. This is the first report of a serum-free medium that ...
TY - JOUR. T1 - Tumor necrosis factor-α is decreased in the umbilical cord plasma of patients with severe preeclampsia. AU - Kupferminc, Michael J.. AU - Peaceman, Alan M.. AU - Dollberg, Shaul. AU - Socol, Michael L.. PY - 1999/1/1. Y1 - 1999/1/1. N2 - We investigated the role of the fetal immune system in pregnancies complicated by preeclampsia by assessing umbilical cord plasma levels of the cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Nineteen nulliparous patients with severe preeclampsia composed the study group (group A). A comparison group was comprised of 19 healthy nulliparous patients with uneventful pregnancies (group B). Mixed umbilical cord blood was collected immediately after delivery. Plasma was prepared and all samples were assayed for TNF-α and IL-1β by specific enzyme-linked immunoassays (ELISAs). Data are presented as the median with range of values. The length of labor was similar in both groups. TNF-α was detected less frequently in the ...
Autocrine Action of Thrombospondin-2 Determines the Chondrogenic Differentiation Potential and Suppresses Hypertrophic Maturation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Improve Neuropathology and Cognitive Impairment in an Alzheimers Disease Mouse Model Through Modulation of Neuroinflammation
title: Impaired function and epigenetic changes of human cord blood-derived CD133+/C-kit+Lin- endothelial progenitor cells in preeclampsia, doi: none, category: Thesis
This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM, human umbilical cord blood-derived mesenchymal stem cells, in repair of
Although pharmacological methods for treating AD have been discovered, none significantly delay the progression of the disease. However, cell transplantation research using animals modeled with AD has indicated that human umbilical cord blood cells (HUCBCs) can ameliorate some cognitive deficits and reduce the effects of the amyloid-beta (Aβ) plaques, one of the physiological hallmarks of AD, comprised of peptides of 36-43 amino acids. However, the role that HUCBCs play in Aβ clearance has yet to be elucidated ...
TY - JOUR. T1 - Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children. AU - Elliott, Salenna. AU - Roberton, Don M.. AU - Zola, Heddy. AU - MacArdle, Peter J.. PY - 2000/1/1. Y1 - 2000/1/1. N2 - Differential expression of the costimulator molecules CD40 and CD154 on neonatal lymphocytes may be one explanation for limited T-dependent antibody responses in human neonates. CD40 was expressed at similar levels on resting B cells from adults, young children (2-20 months of age) or cord blood. CD40 expression was higher on cord blood B cells compared to adult B cells after stimulation with PMA and ionomycin, but similar on adult and cord blood B cells activated by CD3-stimulated T cells. In contrast to previous reports, cord blood T cells stimulated with PMA and ionomycin expressed adult levels of CD154 initially, but this expression was more transient on cord blood T cells. When adult and cord blood mononuclear cells were stimulated with CD3 mAb, T ...
Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication ...
Diabetes mellitus (DM) is a high risk factor for stroke and leads to more severe vascular and white-matter injury than stroke in non-DM. We tested the neurorestorative effects of delayed human umbilical cord blood cell (HUCBC) treatment of stroke in type-2 diabetes (T2DM). db/db-T2DM and db/+-non-DM mice were subjected to distal middle cerebral artery occlusion (dMCAo) and were treated 3 days after dMCAo with: (a) non-DM + Phosphate buffered saline (PBS); (b) T2DM + PBS; (c) T2DM + naïve-HUCBC; (d) T2DM + miR-126(-/-) HUCBC. Functional evaluation, vascular and white-matter changes, neuroinflammation, and miR-126 effects were measured in vivo and in vitro. T2DM mice exhibited significantly decreased serum and brain tissue miR-126 expression compared with non-DM mice. T2DM + HUCBC mice exhibited increased miR-126 expression, increased tight junction protein expression, axon/myelin, vascular density, and M2-macrophage polarization. However, decreased blood-brain barrier leakage, brain hemorrhage, and miR
Human umbilical cord blood derived CD34+ stem cells are reported to mediate therapeutic effects in stroke animal models. Estrogen was known to protect against ischemic injury. The present study wished to investigate whether the protective effect of CD34+ cells against ischemic injury can be reinforced with complemental estradiol treatment in female ovariectomized rat and its possible mechanism. Experiment 1 was to determine the best optimal timing of CD34+ cell treatment for the neuroprotective effect after 60-min middle cerebral artery occlusion (MCAO). Experiment 2 was to evaluate the adjuvant effect of 17β-estradiol on CD34+ cell neuroprotection after MCAO. Experiment 1 showed intravenous infusion with CD34+ cells before MCAO (pre-treatment) caused less infarction size than those infused after MCAO (post-treatment) on 7T magnetic resonance T2-weighted images. Experiment 2 revealed infarction size was most significantly reduced after CD34+ + estradiol pre-treatment. When compared with no treatment
Umbilical cord blood-derived endothelial colony-forming cells (UCB-ECFC) show utility in neovascularization, but their contribution to osteogenesis has not been defined. Cocultures of UCB-ECFC with human fetal-mesenchymal stem cells (hfMSC) resulted in earlier induction of alkaline phosphatase (ALP) (Day 7 vs. 10) and increased mineralization (1.9x; p < .001) compared to hfMSC monocultures. This effect was mediated through soluble factors in ECFC-conditioned media, leading to 1.8-2.2x higher ALP levels and a 1.4-1.5x increase in calcium deposition (p < .01) in a dose-dependent manner. Transcriptomic and protein array studies demonstrated high basal levels of osteogenic (BMPs and TGF-βs) and angiogenic (VEGF and angiopoietins) regulators. Comparison of defined UCB and adult peripheral blood ECFC showed higher osteogenic and angiogenic gene expression in UCB-ECFC. Subcutaneous implantation of UCB-ECFC with hfMSC in immunodeficient mice resulted in the formation of chimeric human vessels, ...
Kim DS, Kim JH, Lee JK, Choi SJ, Kim JS, Jeun SS, Oh W, Yang YS, Chang JW. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev. 2009 Apr; 18(3):511-9 ...
There are several advantages of using umbilical cord blood stem cells over bone marrow stem cells for transplants (see Table 2). The first advantage is that umbilical cord blood is relatively easy to collect and process. Once considered a substance to be thrown away after a birth, now the cord blood can be easily saved. After it is saved and sent to a storage facility, the cord blood is quickly available for use within days to weeks after processing. In contrast, bone marrow stem cells can take much longer to find a match, collect the sample, and process. The process for bone marrow transplantation can take from weeks to months. The collection process for cord blood is not painful to either mother or child and can be done either prior to or after the delivery of the placenta (Gonzalez-Ryan, VanSyckle, Coyne, & Glover, 2000; Percer, 2009). Bone marrow transplants, on the other hand, require the donor to be hospitalized, anesthetized, and experience postcollection pain and discomfort. Thus, ...
Dendritic cells (DC) generated from human umbilical cord blood might replace patients' DC in attempts to elicit tumor-specific immune response in cancer patients. We studied the efficiency of transfection of human cord blood DC with plasmid DNA carrying the enhanced version of green fluorescent protein (EGFP) as a reporter gene, to test if nonviral gene transfer would be a method to load DC with protein antigens for immunotherapy purposes. Cord blood mononuclear cells were cultured in serum-free medium in the presence of granulocyte-monocyte colony stimulating factor (GM-CSF), stem cell factor (SCF) and Flt-3 ligand (FL), to generate DC from their precursors, and thereafter transfected by electroporation. Maturation of DC was induced by stimulation with GM-CSF, SCF, FL and phorbol myristate acetate (PMA). Transfected DC strongly expressed EGFP, but transfection efficiency of DC, defined as HLA-DR+ cells lacking lineage-specific markers, did not exceed 2.5%. Expression of the reporter gene ...
This is an open-label, delayed-treatment trial.. A total of 12 subjects fulfill the inclusion and exclusion criteria will be recruited and randomly assigned into two treatment group. Group A (early-treatment group) will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0. Group B (delayed-treatment group) will participate in 6 months observation before the UCBMC transplantation at Month 6. All subjects will be followed up for 18 months from enrollment at Day 0. Long-term follow-up will be carried up to 36 months if applicable.. The adverse events and safety parameters will be collected and recorded. In addition, the stroke scores , gait and brain MRI will be obtained before and after the treatment to assess the safety and potential treatment effect of UCBMC in chronic ischemic stroke. ...
This is an open-label, delayed-treatment trial.. A total of 12 subjects fulfill the inclusion and exclusion criteria will be recruited and randomly assigned into two treatment group. Group A (early-treatment group) will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0. Group B (delayed-treatment group) will participate in 6 months observation before the UCBMC transplantation at Month 6. All subjects will be followed up for 18 months from enrollment at Day 0. Long-term follow-up will be carried up to 36 months if applicable.. The adverse events and safety parameters will be collected and recorded. In addition, the stroke scores , gait and brain MRI will be obtained before and after the treatment to assess the safety and potential treatment effect of UCBMC in chronic ischemic stroke.. ...
De Wynter, E.A., Buck, D., Hart, C., Heywood, R., Coutinho, L.H., Clayton, A., Rafferty, J.A., Burt, D., Guenechea, G., Bueren, J.A., Gagen, D., Fairbairn, L.J., Lord, B.I. & Testa, N.G. (1998) CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells, 16, 387-396. ...
BACKGROUND: Human umbilical cord blood (HUCB) is a possible alternative to bone marrow (BM) and mobilized peripheral blood (PB) for transplantation of hematopoietic progenitors. The aim of this study was to evaluate the phenotypic profile of CD34+ progenitors present in HUCB. MATERIALS AND METHODS: A flow cytometric analysis was performed on 20 HUCB samples, using a large panel of monoclonal antibodies recognizing different lineage or activation antigens, in double labeling with CD34. RESULTS: A toal of 13,897 +/- 2,529 cells/microL, 0.84 +/- 0.83% of which were CD34+, was found. The large majority of CD34+ cells were committed toward initial myeloid differentiation (CD33+, CD13+) and expressed the transferrin receptor (CD71). A substantial proportion of these cells (about 40%) co-expressed CD45RA and CD117, while a very small number displayed markers of advanced myeloid commitment, such as CD14, CD15 and CD41 (less than 2%), or those of lymphoid differentiation: CD2, CD5, CD7, CD10 and CD19 ...
A Ph.D. student of mine had purchased a reagent she needed for her cell culture work on her thesis. The reagent was not high-tech or anything sensitive of that nature. I do not know whether anyone is interested, but she is working on a very novel topic ie; to study the effect of certain neurotransmitters on cord blood cells, which are now highly regarded in transplantation studies. She had ordered the reagent from a local company who dealt with an American producer on the other side. When she had received the reagent she found that the production label and lot number did not match with the company information provided ...
TY - JOUR. T1 - Role of HIF-1α-activated Epac1 on HSC-mediated neuroplasticity in stroke model. AU - Lin, Chen Huan. AU - Lee, Hsu Tung. AU - Lee, Shin Da. AU - Lee, Wei. AU - Cho, Chin Wen Chental. AU - Lin, Shinn Zong. AU - Wang, Hsiao Jung. AU - Okano, Hideyuki. AU - Su, Ching Yuan. AU - Yu, Yung Luen. AU - Hsu, Chung Y.. AU - Shyu, Woei Cherng. PY - 2013/10. Y1 - 2013/10. N2 - Exchange protein activated by cAMP-1 (Epac1) plays an important role in cell proliferation, cell survival and neuronal signaling, and activation of Epac1 in endothelial progenitor cells increases their homing to ischemic muscles and promotes neovascularization in a model of hind limb ischemia. Moreover, upregulation of Epac1 occurs during organ development and in diseases such as myocardial hypertrophy, diabetes, and Alzheimers disease. We report here that hypoxia upregulated Epac1 through HIF-1α induction in the CD34-immunosorted human umbilical cord blood hematopoietic stem cells (hUCB34). Importantly, ...
HONG KONG, July 23, 2014 /PRNewswire-FirstCall/ - China Cord Blood Corporation (NYSE: CO) (CCBC or the Company), Chinas leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, and Cordlife Group Limited (Cordlife), a multi-product healthcare company catering to the mother and child segment, today announced that the two companies have joined forces in assisting patients across the PRC, Singapore, Hong Kong, Indonesia, India, the Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy. Under the Memorandum of Understanding signed between the two companies, Cordlife, on behalf of its patients who are in need of cord blood stem cell therapy, can facilitate the process by providing relevant information to CCBC, who will then perform searches for possible matching units among its donated cord blood samples in the PRC. For patients who reside in the PRC, CCBC may seek Cordlifes ...
Tytuł projektu: Rozbudowa i przekształcenie bibliograficznej bazy danych AGRO w bazę bibliograficzno-abstraktową z wykorzystaniem oprogramowania YADDA. Nr umowy: POIG 02.03.02-00-031/09 (okres realizacji 2009-2013 ...
Background & aim: This study aimed to determine the relationship between lipid and apolipoprotein B-100 (apo B-100) levels in maternal and umbilical cord sera as well as the effects of these components on anthropometric measurements of newborn infants. Methods:This correlational study was performed on 85 appropriate for gestational age (AGA) newborns and their mothers. For analysis, 5 ml of maternal blood and 5 ml of umbilical venous cord blood were obtained during labor and immediately after delivery, respectively. Sera were separated by centrifugation and analyzed on the same day for estimation of lipid profile including total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B-100. Also, anthropometric indices of newborn infants were measured and recorded. Pearsons correlation coefficient was used to determine the relationship between variables. Results: There was a positive correlation between
Heng, B.C.,Phan, T.T.,Liu, H.,Ouyang, H.W.,Cao, T. (2006). Can the therapeutic advantages of allogenic umbilical cord blood-derived stem cells and autologous bone marrow-derived mesenchymal stem cells be combined and synergized?. ASAIO Journal 52 (6) : 611-613. [email protected] Repository. https://doi.org/10.1097/01.mat.0000235330.02549.78 ...
Researchers found that a protein in human umbilical cord plasma improved learning and memory in older mice, but there's no indication it would work in people.
Background Few studies have examined sex-specific associations of maternal gestational glycemia with cord blood hormones, which might predict later health. Methods In 976 women without pre-existing diabetes in the Project Viva cohort, we used linear regression to examine associations of maternal gestational glycemia with cord hormone concentrations, adjusted for maternal characteristics and stratified by infant sex. Results A total of 6.1% of women had gestational diabetes mellitus (GDM), 8.8% isolated hyperglycemia, 3.2% gestational impaired glucose tolerance, and 81.9% were normoglycemic. In boys, compared with infants of normoglycemic mothers, infants of GDM mothers had higher cord levels of IGF-2 (β 35.55 ng/mL; 95% CI: 2.60, 68.50), IGFBP-3 (111.2 ng/mL; 5.53, 216.8), insulin (4.66 uU/mL; 2.38, 6.95), C-peptide (0.46 ng/mL; 0.25, 0.67), and leptin (3.51 ng/mL; 1.37, 5.64), but lower IGF-1 (- 6.71 ng/mL; - 12.7, - 0.76, adjusted for IGFBP-3). In girls, GDM offspring had higher cord blood ...
LENEXA, Kan., Oct. 22nd 2015. On Oct. 26, at the 2015 AABB Annual Meeting, Dr. Joanne Kurtzberg will present "Game Changers: New Cord Blood Therapies for the Brain." Dr. Kurtzberg, the pioneer of using umbilical cord blood as an alternative stem cell source for unrelated hematopoietic stem cell transplantation, will address the latest clinical applications for cord blood therapies as well as how cord blood can be used to help the brain.. Dr. Kurtzbergs session is part of the popular "Share the Science" series sponsored by Mediware Information Systems, Inc. and Save the Cord Foundation. Share the Science is typically broadcast as a series of webinars, and is an innovative educational program that brings the latest research and breakthroughs to the industry through unbiased and noncommercial presentations.. The event will be held at the Anaheim Convention Center from 7:00 a.m. to 8:15 a.m. Attendance is free, but space is limited, and registration is required. To register, go to ...
Fetal blood sampling is a procedure to remove a small amount of blood from the fetus during pregnancy. In the past, fetal blood sampling was used only during labor through the mothers open cervix to test blood from the fetal scalp for oxygenation. Today, in many perinatal care centers, fetal blood sampling is performed by specially trained perinatologists as part of diagnosing, treating, and monitoring fetal problems at various times during pregnancy. A fetal blood sample may be taken to:. ...
Fetal blood sampling is a procedure to remove a small amount of blood from the fetus during pregnancy. In the past, fetal blood sampling was used only during labor through the mothers open cervix to test blood from the fetal scalp for oxygenation. Today, in many perinatal care centers, fetal blood sampling is performed by specially trained perinatologists as part of diagnosing, treating, and monitoring fetal problems at various times during pregnancy. A fetal blood sample may be taken to:. ...
Rizvanov, AA., Guseva, DS., Salafutdinov, II., Kudryashova, NV., Bashirov, FV., Kiyasov, AP., Yalvaç, ME., Gazizov, IM., Kaligin, MS., Sahin, F., Mukhamedyarov, MA., Palotás, A., Islamov, RR. Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp Biol Med. 236 (1):91-98. 2011 ...
Umbilical cord blood (UCB) banking has become a new medical strength. It offers gravid parents a biological insurance policy that can be used in the event of a child or family members life-grievous illness and puts patients in a position of control over their own treatment options. Still, its graduation to stuffy therapy in the clinical sphere trusts on breakthrough research that will prove its effective for a range of disorders. Booming the multipurpose cells found within the mono nuclear rational of Umbilical cord blood so that capable medication can be attained, abolishing its safety and limitations in HLA- mismatched acquirers, process its executions of action, and proving its substitute in a broad assortment of both rare and common illnesses and diseases are a few of the challenges left to gear. Yet, the tract is moving fast and new UCB- based therapies are on the skyline. ...
To continue increasing the quantity of cord blood samples by paying for a cord collection nurse dedicated to preparing quality cord blood samples as soon as possible after the birth of the babies. Increased of samples will improve the genetic matching of recipients to donors of the samples and thus improve the success rate of overcoming diseases. $75,000 was donated by Lions for cord collection nurses in 2016-17.. To improve the methods of identifying samples with the highest white cell counts and suitability for transplantation. Currently the Foundation has partially funded an up to date database system which greatly increases access to suitable cord blood samples and for the first time will include both Melbourne and Sydney samples leading the way to a future national database system. Up to $100,000 has been allocated for this purpose.. To assist with the funding of equipment such as cryogenic tanks, cryo shippers, centrifuges, etc., when requested by the Cord Blood Bank. The Foundation raises ...
Sterile Cord Blood Collection Unit official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more.
Do many of your patients bring in those cord blood collection kits?? The hospital where Ive been for the past couple of years doesnt get them too often. The MDs arent too used to them. We had